COM:ERYTECH
PHAXIAM Therapeutics
- Stock
Company Overview
| Metric |
|---|
| Company Name |
| Symbol |
| MSH ID |
| Market |
| Sector |
| Industry |
| Country |
| Stage |
| Employee Count |
| Website |
| Founders |
Market Metrics
| Metric |
|---|
| Market Cap |
| Enterprise Value |
| Monthly Web Traffic |
| Web Traffic Growth |
| Valuation |
| Raised Capital |
Financial Performance
| Metric |
|---|
| Revenue |
| Revenue (LTM) |
| Revenue (NTM) |
| Gross Profit |
| EBITDA |
| Operating Income |
| Net Income |
| EPS |
| Diluted EPS |
| Revenue 2022 |
| Revenue 2023 |
| Revenue 2024 |
| Revenue 2025 |
| Revenue 2026 |
Growth Metrics
| Metric |
|---|
| Revenue Growth (LTM) |
| Revenue Growth (NTM) |
| Gross Profit Growth (LTM) |
| EBITDA Growth (LTM) |
| Net Income Growth (LTM) |
| 14-Day Growth Score |
| 28-Day Growth Score |
| 90-Day Growth Score |
| 365-Day Growth Score |
Profitability Ratios
| Metric |
|---|
| Gross Profit Margin |
| Operating Profit Margin |
| EBITDA Margin |
| Net Profit Margin |
| Return on Equity |
| Return on Assets |
| Return on Capital Employed |
Valuation Multiples
| Metric |
|---|
| P/E Ratio |
| P/B Ratio |
| Revenue Multiple (LTM) |
| Revenue Multiple (NTM) |
| EBITDA Multiple (LTM) |
| EBITDA Multiple (NTM) |
| Price to Sales Ratio |
| EV Multiple |
Operational Metrics
| Metric |
|---|
| Days Sales Outstanding |
| Days Payables Outstanding |
| Days Inventory Outstanding |
| Operating Cycle |
| Cash Conversion Cycle |
| Asset Turnover |
Cash Flow Metrics
| Metric |
|---|
| Operating Cash Flow |
| Free Cash Flow |
| Cash Flow to Debt |
| Operating Cash Flow/Sales |
| Free Cash Flow Yield |
Balance Sheet Metrics
| Metric |
|---|
| Cash & Equivalents |
| Accounts Receivable |
| Inventory |
| Goodwill |
| Debt to Capitalization |
| Debt to Assets |
| Current Ratio |
| Quick Ratio |
Efficiency Metrics
| Metric |
|---|
| Rule of 40 (LTM) |
| Rule of 40 (NTM) |
| Stock Comp to Revenue |
| R&D to Revenue |
| SG&A to Revenue |